CA3154129A1 - Rifabutin treatment methods, uses, and compositions - Google Patents

Rifabutin treatment methods, uses, and compositions Download PDF

Info

Publication number
CA3154129A1
CA3154129A1 CA3154129A CA3154129A CA3154129A1 CA 3154129 A1 CA3154129 A1 CA 3154129A1 CA 3154129 A CA3154129 A CA 3154129A CA 3154129 A CA3154129 A CA 3154129A CA 3154129 A1 CA3154129 A1 CA 3154129A1
Authority
CA
Canada
Prior art keywords
rifabutin
baumannii
composition
cmax
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3154129A
Other languages
English (en)
French (fr)
Inventor
Glenn E. Dale
Sergio Lociuro
Christian Kemmer
Vincent Trebosc
Marc Gitzinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioversys AG
Original Assignee
Bioversys AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioversys AG filed Critical Bioversys AG
Publication of CA3154129A1 publication Critical patent/CA3154129A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3154129A 2019-09-12 2020-08-03 Rifabutin treatment methods, uses, and compositions Pending CA3154129A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962899257P 2019-09-12 2019-09-12
US62/899,257 2019-09-12
US201962902019P 2019-09-18 2019-09-18
US62/902,019 2019-09-18
US201962941160P 2019-11-27 2019-11-27
US62/941,160 2019-11-27
US202062977659P 2020-02-17 2020-02-17
US62/977,659 2020-02-17
PCT/IB2020/000647 WO2021048611A1 (en) 2019-09-12 2020-08-03 Rifabutin treatment methods, uses, and compositions

Publications (1)

Publication Number Publication Date
CA3154129A1 true CA3154129A1 (en) 2021-03-18

Family

ID=72432957

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3154129A Pending CA3154129A1 (en) 2019-09-12 2020-08-03 Rifabutin treatment methods, uses, and compositions
CA3154317A Pending CA3154317A1 (en) 2019-09-12 2020-08-03 Antibiotic combination therapies

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3154317A Pending CA3154317A1 (en) 2019-09-12 2020-08-03 Antibiotic combination therapies

Country Status (17)

Country Link
US (6) US11207305B2 (enExample)
EP (3) EP4420673A3 (enExample)
JP (4) JP7769605B2 (enExample)
KR (1) KR20220103698A (enExample)
CN (3) CN120860031A (enExample)
AU (2) AU2020344214B2 (enExample)
BR (2) BR112022004645A2 (enExample)
CA (2) CA3154129A1 (enExample)
ES (1) ES2982067T3 (enExample)
HR (1) HRP20240818T1 (enExample)
HU (1) HUE066936T2 (enExample)
MX (1) MX2022003077A (enExample)
PH (1) PH12022550610A1 (enExample)
PL (1) PL4028001T3 (enExample)
RS (1) RS65681B1 (enExample)
SM (1) SMT202400250T1 (enExample)
WO (2) WO2021048611A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230364065A1 (en) 2022-05-16 2023-11-16 BioVersys AG Antibiotic combination therapies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645508B1 (en) * 1999-06-18 2003-11-11 Jivn-Ren Chen Stable L-ascorbic acid composition
CN101362067A (zh) * 2007-08-06 2009-02-11 天津科技大学 一种微胶囊制备方法
CA2714043C (en) * 2008-02-08 2016-11-08 Giaconda Limited Methods and compositions for treating inflammatory bowel disease
MY158809A (en) 2010-09-22 2016-11-15 Craun Res Sdn Bhd Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same
EA016410B1 (ru) 2010-11-13 2012-04-30 Ооо "Нпк Наносистема" Фармацевтическая композиция на основе наночастиц циклодекстрина, содержащих рифабутин, способ ее получения, способ лечения микобактериоза и геликобактерной инфекции (варианты)
EP2670417A4 (en) * 2011-01-31 2014-07-09 Us Army METHOD AND COMPOSITIONS FOR TREATING BACTERIAL INFECTIONS WITH IRON RADIATORS
CN102178604B (zh) 2011-03-22 2014-03-05 中国人民解放军第三0九医院 凝胶微球制备装置、方法及可注射抗结核药物凝胶微球
RU2472512C1 (ru) * 2011-12-06 2013-01-20 Общество С Ограниченной Ответственностью "Ибмх-Экобиофарм" Противотуберкулезная композиция и способ ее получения
WO2016013986A1 (en) * 2014-07-25 2016-01-28 Agency For Science, Technology And Research Antibiotic compositions for treating bacterial infections
HK1243740A1 (zh) * 2014-09-04 2018-07-20 Labrador Diagnostics Llc 病原体和抗微生物剂抗性检测
US9763996B2 (en) 2015-01-16 2017-09-19 Northern Antibiotics, Ltd. Polymyxin derivative and uses thereof
WO2016178240A1 (en) * 2015-05-04 2016-11-10 Gufic Biosciences Limited A freeze dried pharmaceutical formulation of rifabutin and process for preparation thereof
JP7072898B2 (ja) * 2016-08-16 2022-05-23 ユニバーシティ オブ ロチェスター ポリミキシンｂ／トリメトプリム系の治療薬を含有する医薬組成物
AU2018219149A1 (en) * 2017-02-07 2019-09-19 Unm Rainforest Innovations Isotope enhanced ambroxol for long lasting autophagy induction
US11701346B2 (en) * 2018-11-28 2023-07-18 University Of Southern California Rifabutin for the treatment of acinetobacter baumannii

Also Published As

Publication number Publication date
HRP20240818T1 (hr) 2024-10-11
AU2020347536B2 (en) 2025-09-25
JP7804570B2 (ja) 2026-01-22
US12257241B2 (en) 2025-03-25
ES2982067T3 (es) 2024-10-14
PL4028001T3 (pl) 2024-07-22
MX2022003077A (es) 2022-07-11
US20240041845A1 (en) 2024-02-08
JP2026016690A (ja) 2026-02-03
EP4420673A2 (en) 2024-08-28
US20210077471A1 (en) 2021-03-18
EP4028000A1 (en) 2022-07-20
US20220184048A1 (en) 2022-06-16
WO2021048610A1 (en) 2021-03-18
US20210077472A1 (en) 2021-03-18
PH12022550610A1 (en) 2023-03-13
CA3154317A1 (en) 2021-03-18
AU2020344214A1 (en) 2022-04-21
JP2022548252A (ja) 2022-11-17
CN120860031A (zh) 2025-10-31
BR112022004645A2 (pt) 2022-06-21
KR20220103698A (ko) 2022-07-22
US11766425B2 (en) 2023-09-26
RS65681B1 (sr) 2024-07-31
SMT202400250T1 (it) 2024-07-09
CN114980889A (zh) 2022-08-30
CN115052597A (zh) 2022-09-13
AU2020344214B2 (en) 2026-01-22
US11833139B2 (en) 2023-12-05
US20230132691A1 (en) 2023-05-04
CN115052597B (zh) 2025-07-08
US11351158B2 (en) 2022-06-07
HUE066936T2 (hu) 2024-09-28
EP4420673A3 (en) 2024-11-06
EP4028001C0 (en) 2024-04-10
EP4028001B1 (en) 2024-04-10
AU2020347536A1 (en) 2022-04-14
JP2022551228A (ja) 2022-12-08
BR112022004672A2 (pt) 2022-06-07
WO2021048611A1 (en) 2021-03-18
EP4028001A1 (en) 2022-07-20
JP7769605B2 (ja) 2025-11-13
JP2025176113A (ja) 2025-12-03
US11207305B2 (en) 2021-12-28
US20250281469A1 (en) 2025-09-11

Similar Documents

Publication Publication Date Title
Estes et al. Present and future therapeutic strategies for melioidosis and glanders
Baucheron et al. TolC but not AcrB is essential for multidrug-resistant Salmonella enterica serotype Typhimurium colonization of chicks
US20250281469A1 (en) Rifabutin treatment methods, uses, and compositions
US20230381157A1 (en) Rifabutin for the treatment of acinetobacter baumannii
US10064860B2 (en) Pharmaceutical compositions containing clofazimine for inhibiting Clostridium difficile activity
Wang et al. Simultaneous functional disruption of the iron acquisition system and type VI secretion system results in complete suppression of virulence in Acinetobacter baumannii
JP7638263B2 (ja) マイコプラズマ・ジェニタリウムによって引き起こされる感染症の治療のための組合せ
Hu et al. Mefloquine enhances the activity of colistin against antibiotic-resistant Enterobacterales in vitro and in an in vivo animal study
US20250099458A1 (en) Use of anti-idiopathic pulmonary fibrosis drug nintedanib in treatment of tuberculosis
HK40115867A (en) Rifabutin treatment methods, uses, and compositions
US11246905B2 (en) Treating infections using IdsD from Proteus mirabilis
US7595328B2 (en) Methods of use of quinolone compounds against pneumococcal and Haemophilus bacteria
WO2018160104A1 (ru) Композиция антимикробных препаратов для лечения инфекционных заболеваний людей и животных и способ её применения
WO2020014709A1 (en) Compounds, compositions, and methods for the treatment and prevention of avian pathogenic e. coli (apec)
CN102138917A (zh) 二甲基黄青霉素在制备抗结核药物中的应用
Lopez Galdeano World Microbe Forum 2021. Virtual-June 20-24, 2021
WO2018070874A1 (en) Means and methods for reducing or avoiding antibiotic resistance and spread of virulence in human pathogens
KR20220151426A (ko) 병원성 비브리오균의 병원성인자 발현 억제용 약학적 조성물
KR20230085579A (ko) 항병원성 활성 및 바이오필름 형성 억제 효과를 나타내는 화합물의 신규한 용도
CN110141569A (zh) 抗牛多杀性巴氏杆菌的药物组合物
ITRM20120429A1 (it) 5-fluorocitosina come agente antibatterico
TW201036609A (en) Compound for the treatment of tuberculosis

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240320

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240730

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240730

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240730

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250324

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250610

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250610

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-T10-T11-T100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXTENSION OF TIME FOR TAKING ACTION REQUEST RECEIVED

Effective date: 20250722

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250923

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: A-2-2-T10-T13-T101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXTENSION OF TIME FOR TAKING ACTION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251124

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251124

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260402

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260416

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260421

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260421

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260430